Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents
in clinical use both of lung cancer in mono-and combination therapies. However, platinum …

The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has
led to unprecedented clinical response in a subset of lung cancer patients carrying the …

Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …

Increasing evidence has suggested that high expression level of cyclooxygenase-2 (Cox-2)
is associated with the malignancies of non–small cell lung cancer (NSCLC), leading to a …

BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …

Lung cancer remains a significant cause of mortality worldwide. While advances in therapy
continue to be made, the overall prognosis for patients diagnosed with lung cancer remains …

Abstract Purpose: Cyclooxygenase-2 (COX-2) plays important roles in the modulation of
apoptosis, angiogenesis, immune response, and tumor invasion. Elevated COX-2 …

Designing optimal (neo) adjuvant therapy is a crucial aspect of the treatment of non-small-
cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and …

Abstract Background Fei-Liu-Ping (FLP) ointment is an oral prescription medication that has
been widely applied to treat lung cancer patients in China. Regulation of the metastatic …

Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in
several epithelial malignancies, including head and neck squamous cell carcinoma …